Drug Firms Buy $67.5 Million Voucher to Speed FDA Review

Regeneron Pharmaceuticals and Sanofi are spending $67.5 million to buy a special voucher held by BioMarin Pharmaceuticals in a bid to hasten regulatory review of their new cholesterol drug.



from WSJ.com: US Business http://ift.tt/1zxrNJ0

via IFTTT